AssetMark’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
AssetMark's DNLI Position: Q3 2026 in Review
AssetMark increased its Denali Therapeutics (DNLI) stake by 18% in Q3 2026, buying an estimated $21.6K and bringing the position to 6,137 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1586.
AssetMark first reported a position in DNLI in Q3 2022 and has held it in 17 quarters since. The position peaked at $134K in Q2 2026. 223 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- AssetMark held 6,137 shares of Denali Therapeutics worth $127K as of Q3 2026.
- AssetMark bought 921 Denali Therapeutics shares in Q3 2026, an estimated $21.6K.
- Denali Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1586 holding.
- AssetMark first reported a position in Denali Therapeutics in Q3 2022 and has held it in 17 quarters since.
- AssetMark's Denali Therapeutics position peaked at $134K in Q2 2026.
- 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.